lifestyle.thedishh.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Skye Bioscience, Inc.
Skye Bioscience Presenting at GLP-1-Based Therapeutics Summit
May 2, 2026
Skye Bioscience Treats First Patient in Nimacimab Higher-Dose Expansion Study Evaluating Exposure-Response to Inform Phase 2b Dose Selection for GLP-1 Combination Development
May 1, 2026
Skye Bioscience Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
March 11, 2026
Skye Bioscience to Announce 2025 Financial Results and Business Update on March 10, 2026
March 5, 2026
Skye Reports Positive CBeyond Phase 2a Extension Interim Study Results for Nimacimab in Combination With Semaglutide
February 7, 2026
Skye Bioscience Highlights Attributes of its Peripherally-restricted CB1 Inhibitor Antibody at Keystone Obesity Conference
January 29, 2026
Skye Bioscience to Present Poster at Keystone Obesity Conference
January 21, 2026